VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not demonstrated significant clinical benefit in patients with prostate cancer. To identify additional immune inhibitory pathways in the prostate tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors fr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Gao, Jianjun, Ward, John F, Pettaway, Curtis A, Shi, Lewis Z, Subudhi, Sumit K, Vence, Luis M, Zhao, Hao, Chen, Jianfeng, Chen, Hong, Efstathiou, Eleni, Troncoso, Patricia, Allison, James P, Logothetis, Christopher J, Wistuba, Ignacio I, Sepulveda, Manuel A, Sun, Jingjing, Wargo, Jennifer, Blando, Jorge, Sharma, Padmanee
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466900/
https://ncbi.nlm.nih.gov/pubmed/28346412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados